Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.40

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr597.13M

Enterprise Valuekr581.44M

Total Cash (Recent Filing)kr26.06M

Total Debt (Recent Filing)kr661.00K

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Jul 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (very Low Leverage)Extremely low debt (debt-to-equity ~0.01) materially reduces refinancing and near-term solvency risk. This financial conservatism gives the company time to execute turnaround plans or fund commercialization without immediate refinancing pressure, supporting endurance through multi-quarter losses.

Durable Gross Margins (~61%)A ~61% gross margin indicates strong product-level economics and potential pricing power for ColdZyme. High gross margins provide structural room to invest in marketing and R&D while absorbing distribution costs, aiding margin recovery if operating expenses are rationalized over the medium term.

Established Product And Partner Commercialization ModelOwning a recognized consumer-health product with both direct sales and partner licensing diversifies go-to-market risk. The partner network enables broader geographic reach without full local cost bases, supporting sustainable revenue streams and scalable market expansion over several quarters to years.

Bears Say

Persistent Heavy Losses (deep Negative Margins)Net margin near -96% shows losses are extreme and structural rather than cyclical. Such persistent unprofitability erodes equity and places a high bar on management to demonstrate durable operating improvements, making multi-quarter recovery and shareholder value restoration challenging.

Structural Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow (~-39.2m and -27.8m TTM) indicate the business consumes cash to run operations, requiring ongoing financing or dilution unless cash conversion improves. This raises medium-term execution and funding risk for commercialization and R&D.

Stagnant To Weakening Revenue TrendsFlat TTM revenue with a sharply negative growth rate signals loss of momentum in core markets. Without clear revenue expansion, leverage from high gross margins cannot offset fixed costs, making sustained profitability difficult and increasing dependence on cost cuts or new market breakthroughs.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.40 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr597.13M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Jul 16, 2026 which is in 8 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Apr 28, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.